Unmet Needs and Future Outlook for HER2-Targeted Therapies

Panelists discuss how:
Despite major progress, unmet needs persist in optimizing HER2-targeted treatment sequences and addressing resistance mechanisms. The experts explore how next-generation ADCsantibody-drug conjugates, bispecific antibodies, and HER3-targeted drugs may close therapeutic gaps. They emphasize ongoing clinical trials that aim to extend the benefits into HER2-low and resistant populations. The discussion concludes with optimism for integrating molecular diagnostics, real-world evidence, and multidisciplinary collaboration to continue improving patient outcomes.